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ABSTRACT 
Objective: To assess the long-term impact (minimum of 3 years 
follow-up) of polymorphisms in cytokine genes in donor:recipient 
pairs on the results of the transplant. Methods: We compared 
genetic cytokine polymorphisms and the primary factors of risk for the 
development of chronic rejection in paired groups of renal transplant 
patients with and without chronic allograft nephropathy [CAN]. 
Results:  Multivariate analysis indicated that the presence of the high-
production TT genotype (codon 10) of the transforming growth factor 
beta-1 (TGFB1) was protective in receptors (p=0.017), contrasting 
with the increased risk when present in donor samples (p=0.049). 
On the other hand, in the case of the gamma interferon studied, 
the greater frequency of the high production allele was protective 
in the analysis of the donor group (p=0.013), increasing the risk of 
chronic nephropathy of the allograft when present in the recipients 
(p=0.036). Conclusion: Our results highlight the importance of TGFB1 
genotyping in donors, and indicate that polymorphisms in the gene of 
this cytokine in donor cells might contribute to the development of 
chronic allograft nephropathy 
Keywords: Chronic renal allograft dysfunction; Genetic 
polymorphism; Donor genotype; Transforming growth factor beta-1; 
Interferon-gamma
RESUMO  
Objetivo: Avaliar o impacto de longo prazo (com seguimento mínimo de 2 
anos) de polimorfismos em genes de citocinas em pares doador:receptor 
sobre os resultados do transplante. Métodos: Comparamos os 
polimorfismos genéticos das citocinas e os principais fatores de risco para 
o desenvolvimento de rejeição crônica em grupos pareados de pacientes 
transplantados renais com e sem nefropatia crônica do aloenxerto [CAN]. 
Resultados: A análise multivariada indicou que a presença do genótipo 
TT (códon 10) de alta produção do fator de crescimento transformador 
beta-1 (TGFB1) era protetor nos receptores (p=0,017), em contraste 
com o risco aumentado quando presente nas amostras de doadores 
(p=0,049). Por outro lado, no caso do interferon gama estudado, a maior 
frequência do alelo de alta produção foi protetora na análise do grupo 
de doadores (p=0,013), mas aumentava o risco de nefropatia crônica 
do aloenxerto quando presente nos receptores (p=0,036). Conclusão: 
Nossos resultados ressaltam a importância da genotipagem de TGFB1 
também em doadores, e indicam que polimorfismos no gene desta 
citocina em células do doador podem contribuir no desenvolvimento da 
nefropatia crônica do aloenxerto.
Descritores: Disfunção renal crônica do aloenxerto; Polimorfismo 
genético; Genótipo do doador; Fator transformador de crescimento-beta 1; 
Interferon gama
INTRODUCTION
In spite of accumulated knowledge, the reasons why 
some patients, but not others, with similar clinical 
backgrounds, develop chronic rejection after renal 
transplantation are still unclear. The inflammatory 
nature of rejection has led to the query on the 
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contribution of cytokine gene polymorphisms to the 
outcome of solid organ grafting, especially in the case 
of kidneys. Initial studies starting over 10 years ago, in 
renal transplanted patients, highlighted an association 
between the high production -308 TNFA allele and a 
low production IL10 genotype with acute rejection (1, 2) 
and polymorphic IFNG CA repeat and IL10 genotype 
in chronic rejection (2). 
Chronic allograft nephropathy (CAN) is 
identified by a progressive decline in renal function, 
and presents with typical histological features. These 
include the hallmarks of inflammatory processes, 
such as mononuclear cell infiltration, perivascular 
and interstitial inflammation, fibrosis, hyperplasia 
of the intima leading to partial or total decrease 
of the vascular lumen, tubular atrophy, and even 
glomerulosclerosis and ischemia. After 10 years, 
over 50% of patients will have developed CAN (3) 
culminating with a loss of the graft itself. In spite of the 
ever-increasing improvement of immunosuppressive 
protocols, CAN still remains a major problem partly 
as a result of the use of calcineurin inhibitors. In 
addition, a variety of factors have been reported 
associated with the development and progression 
of CAN. Donor/recipient HLA (Human Leukocyte 
Antigen) disparity, the basis of alloreactivity and 
acute rejection, is a major risk factor; donor age,  graft 
cold ischemia time, the number of acute rejection 
episodes, hyperlipoproteinemia, hypertension, and 
CMV infection episodes have also been established 
as factors in the progression of chronic allograft 
dysfunction (reviewed in detail in (4, 5). 
In the initial phases of CAN, increased HLA 
expression and inflammatory cytokines such as IL-1 
(Interleukin 1), IFN-γ (Interferon gamma), and TNF-α 
(Tumor necrosis factor alpha), in addition to MCP-1 
(Monocyte chemotactic protein 1) are present, as 
mononuclear cells infiltrate the kidney and adhere to 
the endothelium. At a later stage, concomitant to the 
proliferation of myofibroblasts and intimal hyperplasia, 
cytokines shift to a type 2 profile, which includes IL-4, 
IL-10, and TGF-β1 (transforming growth factor beta 1), 
as well as PDGF (platelet-derived growth factor) and 
EGF (epidermal growth factor)(6). This combination of 
factors is responsible for the phenotypic transformation 
of fibroblasts into myofibroblasts (7). Endothelium and 
smooth muscle cells stain brightly for TNF-α, PDGF, 
and TGF-β1 (8). TGF-β1 is also expressed on fibroblasts 
and areas of fibrosis (9). Though immunohistochemistry 
studies show that TGF-β1 is present in biopsies from 
kidneys with either acute or chronic rejection, a clearly 
enhanced staining of the interstitium is observed in 
chronic rejection (10). Finally, cyclosporine A, the major 
immunosuppressant drug used in renal transplanted 
patients, has been shown to induce TGF-β1 production 
in a proximal tubular cell line (11), and a similar effect has 
been described for tacrolimus (12). On the other hand, 
TGF-β1 has been repeatedly reported as a regulatory 
cytokine playing an important role in many models 
of tolerance, contributing to the immunosuppressive 
capacity of circulating CD4+CD25+ T lymphocytes in 
vivo (13) .
OBJECTIVE
In this study, we investigated genetic polymorphisms 
of some cytokine genes involved in the first steps and in 
the progression of atherosclerosis, in addition to known 
effector-phase and regulatory cytokines, aiming to 
identify susceptibility genes for CAN  (14). Polymorphisms 
of candidate cytokine genes were compared between 
groups of donor/recipient pairs with or without CAN, 
which were matched as best possible for major risk 
factors for CAN, such as level of HLA disparities, type 
and age of donor, number of acute rejection episodes, 




This retrospective case:control study comparing two 
groups of patients, included patients who underwent 
renal transplantation and their respective donors at 
Hospital das Clínicas, University of São Paulo School of 
Medicine. The Ethics Committee approved this study 
and subjects gave their informed consent for blood 
sampling. Renal biopsies were performed according 
to clinical indications and classified according to Banff 
criteria (15). DNA samples from 102 donor/recipient 
kidney transplant pairs were analyzed. Most patients 
received their transplant between 1995 and 2000. Of 
these, 56 recipients experienced biopsy-proven CAN 
and 46 were free of CAN with a minimum follow-up 
of 39 months. The two groups were comparable for 
major risk factors such as HLA compatibility (with two 
exceptions, all donor:recipient pairs were haploidentical 
or non-identical), level of previous sensitization, number 
of transfusions, and number of acute rejection episodes. 
Groups were also matched for progression factors 
such as donor type (living-related or unrelated) and 
age, presence of hypertension, hypercholesterolemia, 
and presence of anti-CMV IgG antibodies. The 
majority of patients were treated with conventional 
triple immunosuppressive therapy with cyclosporine, 
azathioprine, and prednisone. However, 68% of the 
patients were switched to MMF upon diagnosis of CAN, 
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and some of the more recently transplanted patients 
received MMF from early on. Demographic features 
are shown in Table 1.
DNA extraction and genotyping
Blood samples were drawn and DNA extracted by 
DTAB/CTAB (Dodecyltrimethylammonium bromide/
Cetyltrimethylammonium bromide)(16) or alternatively 
by salting-out methods (17) as described elsewhere. 
Unless otherwise mentioned, cytokine genotyping of 24 
SNPs (single nucleotide polymorphisms) in 18 genes was 
performed by PCR-SSP (polymerase chain reaction with 
sequence-specific primers) on ready trays designed for 
the 13th International Histocompatibility Workshop on 
Cytokine Polymorphism by the Collaborative Transplant 
Study center in Heidelberg (http://www.ctstransplant.
org/public/reagents.shtml). Briefly, PCR-SSP typing by 
the Heidelberg kit consisted of 48 PCR primer mixes 
dispensed in 96-well PCR trays. Master mix (MgCl2 
buffer, dNTPs, and glycerol) was combined with 20 U 
Taq polymerase and 1.2 - 3.0 µg DNA, and dispensed 
onto the trays. Products were electrophoresed on 2% 
agarose gel and interpreted as defined by the Workshop 
protocol. The Heidelberg kit allowed SNP haplotyping 
for IL1B (-511 C/T and +3692 C/T), TGFB1 (codon 10 
C/T and 25 G/C), TNFA (-238 G/A , and -308 G/A) , 
IL2 (-330 T/G and +160 G/T), IL4 (-1098 T/G, -590 C/T 
and -33 C/T), IL6 (-174 G/C, nt565 G/A), IL10 (-1082 
G/A,-819 T/C and -590 A/C), and ICAM1 (G6241R 
and E465D) genes. The tray also permitted typing for 
single SNPs in genes coding for IFNG (3´UTR5644 
A/T), IL1A (-889 C/T), IL1R (pst1970 C/T), IL1RN 
(mspa111100 C/T), IL12B (-1188 A/C), and IL4RA 
(+1902 G/A). MCP1 SNP at position -2518 (A/G) was 
analyzed by PCR-RFLP, using the following primers: 
forward CCGAGATGTTCCCAGCACAG and reverse 
CTGCTTTGCTTGTGCCTCTT (18). 
Statistical analysis
Bivariate analyses were carried out, using CAN 
as the dependent variable and the different gene 
polymorphisms investigated as independent variables. 
Variables significant in the bivariate analyses were 
the first entered into the multiple logistic regression 
models, but all other variables were tested. Two criteria 
were used to keep variables in the final model: statistical 
significance (p<0.05) or a clear change in the estimates 
of the effects of some polymorphisms produced by 
those not selected in the first step of the analysis (19). 
The analyses were performed using STATA software, 
version 8.0.
RESULTS
We analyzed 17 different gene polymorphisms, 
mostly cytokines associated with inflammation and/
or atherosclerosis, in both donor and recipient DNA 
samples. There was no deviation from expected Hardy-
Weinberg proportions in any of the genes analyzed. 
Most SNPs analyzed, including those from IL1B (2 
SNPs), IL4 (3 SNPs), IL10 (3 SNPs), ICAM1 (2 SNPs), 
and MCP1, were equally distributed in groups with 
and without CAN, in donor and in recipient samples. 
Preliminary analyses led us to discard TNFA, IL2, IL6, 
and IL12B as non-informative in our population due to 
their very low frequency in the healthy population, and 
were not tested further. A summary of the allele and 
haplotype frequencies in all groups is shown in Table 2.
In the case of IL1A and IL1B, which are neighboring 
genes only about 60 kb apart, typing of IL1A alleles 
in position -889, and IL1B SNPs at -511 and +3962, 
disclosed at least 6 different haplotypes. However, in 
almost half of the cases, joint IL1A/IL1B haplotypes 
could not be unambiguously defined. In other words, a 
comparison of IL1A/IL1B haplotype distribution in the 
two groups was not possible. 
Of all genes analyzed, the sole significant difference 
disclosed upon Chi-square analysis was the presence 
of the high producer TT genotype in codon 10 of the 
Characteristics Patients with  CAN Patients without  CAN
Pairs 56 46
Gender M/F 26/30 24/22
Living donorsa 39 (69.6%)b 35 (76.0%)
Donor age c 38.37 ± 12.05 34.38 ± 12.13
Histocompatiblity –ID d 3 (5.4%) 0
Histocompatiblity -HAd 25 (44.6%) 23 (50.0%)
Histocompatiblity –NI d 28 (50.0%) 23 (50.0%)
Months of follow-up 118.9 ± 35.8 94.4 ± 31.0
Acute rejection episodes (present) 33 (58.9%) 20 (43.5%)
CMV positive post-transplant 3 4
Hyperuricemia (present) e 28 (50.0%) 20 (30.0%)
Graft loss due to CAN 26 (46.4%)
Mean of creatinine values (mg/dL) 
(last measurement)f
4.27 {1.1-22.0} 1.84 {0.6 - 7.8}
Pre-transplant transfusions (n≥2) 24 (54,5%) 26 (61,9%)
Dyslipidemia 33 (71.7%) 20 (54.1%)
Hypertension 40 (81.6%) 31 (81.6%)
n for multivariate analysis 44 42
Table 1. Demographic and clinical features of the patients with and without 
chronic allograft nephropathy (CAN)
a Obs: 4 (with CAN) and 9 (without CAN) living donors were unrelated (difference not significant)
b Values in parenthesis are percentage of total number of patients in the group
c Values are mean ± standard deviation ( difference not significant by the Student t test for unpaired samples)
d ID - HLA identical donor (sibling; 0/6 mismatches) 
   HA - haploidentical donor 1-3/6 mi’smatches  
   NI - nonidentical  donor 4-6/6 mismatches  
e Information not available in 16 CAN and 6 no CAN patients
f Values in brackets correspond to the span of values found in the group  
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TGFB1 gene (χ2 = 6.547, p = 0.0379), present in almost 
40% of transplant recipients with CAN, compared to 
15% in the group free of CAN. 
In the multivariate analysis, the IL1A low 
production allele was shown to be marginally 
protective when present in the graft (p=0.052). Results 
of the multivariate analysis can be seen in Table 3. 
More importantly, the high production TGFB1 TT 
genotype (codon 10) was protective in recipients 
(p=0.017) but conferred increased risk when present 
in donor samples (p=0.049). Conversely, in the case 
of IFNG polymorphism, the high production allele 
was protective in the donor analysis (p=0.013), but 
increased the risk of CAN when present in recipients 
(p=0.036). Finally, in spite of our careful matching of 
groups with and without CAN, and in accordance with 
published literature, acute rejection was confirmed 
as a risk factor for CAN (p=0.024). Hyperuricemia 
was analyzed in a smaller sample (67 instead of 86 
pairs) and was also shown to be a risk factor for CAN 
(p=0.013, C.I. 1.628-63.437, data not shown). On the 
other hand, donor type, donor age, number of HLA 
disparities, presence of hypertension, dyslipidemia, 
number of pre-transplant transfusions, and months of 
follow-up, also included in the multivariate analysis, 
were equally distributed, and thus did not impact the 
result of the analysis.
DISCUSSION
Our case:control analysis of individual gene 
polymorphisms disclosed a significant increase of the 
TGFB1 high production genotype  in  donors from the 
group with CAN. There was a trend toward significance 
in several other cytokine gene polymorphisms analyzed, 
however the relatively low number of patients in this 
study impacts upon this type of analysis. Thus, in order 
to counterbalance the lower power of the individual 
analysis we employed a multivariate analysis where 
all variables were taken into account. This analysis 
brought forth clear-cut results, confirming known 
risk factors like acute rejection episodes, as well as 
discriminating protective and risk-conferring cytokine 
gene polymorphisms. This was the case for TGFB1 and 
IFNG. Donor high production TGFB1 TT genotype 
(codon 10) was confirmed in a multivariate analysis 
to be associated with CAN, but the same genotype 
when present in the recipients conferred protection. 
In fact, despite TGF-β1´s short-term tubule-repairing 
effect in the graft, its dominant intra-graft increased 
production seems to have an overall negative effect 
adding to progression of chronic rejection, enhancing 
Allele/Haplotype Frequency (%)1  
Recipient Donor
Gene
SNP position Allele No CAN CAN No CAN CAN
IL1A  C 71.1 69.8 69.6 67.9
-889 T 28.9 30.2 30.4 32.1
IL1B  C 57.7 63.0 59.8 64.8
-511 T 42.3 37.0 40.2 35.2
IL1B C 80.0 80.5 84.8 83.0
3962 T 20.0 19.5 15.2 17.0
IL1R C 63.3 57.4 58.7 57.5
PstI 1970 T 36.7 42.6 41.3 42.5
IL1RA C 35.5 37.7 30.4 33.6
Mspa1 11100 T 64.5 62.3 69.6 66.4
IFNG A 58.9 59.8 60.0 63.2
UTR 5644 T 41.1 40.2 40.0 36.8
IL4* TTT 36.0 32.1 39.1 29.8
-1098/ - 590/ - 33 TCC 51.2 58.0 52.2 55.8
 GTT 1.2 1.2 1.1 4.8
 GCC 11.6 4.9 7.6 7.7
 TTC 0.0 3.8 0.0 1.9
IL10 ACC 30.2 36.7 34.8 39.6
-1082/ -819/ -590 ATA 37.7 27.7 33.7 26.4
GCC 32.1 35.6 31.5 34.0
MCP1 A 73.0 72.0 67.4 73.6
-2518 G 27.0 28.0 32.6 26.4
ICAM1 GG 45.0 37.5 31.7 37.5
G6241R/E465D GA 48.3 53.6 56.7 53.6
 AG 5.0 8.9 11.6 8.9
 AA 1.7 0.0 0.0 0.0
TGFB1** T 56.7 52.8 44.6 57.6
cdn10 C 43.3 47.2 55.4 42.5
TGFB1 G 96.6 92.5 93.5 91.5
cdn25 C 3.4 7.5 6.5 8.5
TGFB1 CG 38.9 39.6 48.9 34.0
cdn10/cdn25 TG 56.7 52.9 44.6 57.5
 CC 4.4 7.5 6.5 8.5
Table 2. Summary of allele and haplotype frequencies in groups with and without 
chronic allograft nephropathy (CAN)
1 According to the literature, alleles associated with high production are:
IL1A (-889*T), IL1B (-511*T; +3962*T), IL1RA (C), IFNG (T), TGFB1 (codon 10*T; codon 25*G), IL4 (-590*T; 
-33*T), IL10 (-1082*G, -819*C, -590*C), MCP1 (-2518*G)
UTR = untranslated region ; Pst1 and Mspa1 = restriction enzymes; cdn = codon 
* IL4, IL10, ICAM1 data are shown in the form of haplotypes 
** TGFB1 data are shown as both allele and haplotype frequencies. TT Genotype (cdn 10) χ2 = 6.547, p = 0.0379
Chronic rejection (CAN) OR ORadj 95%CIadj p-value
Acute cellular rejection 1.87 4.12 1.20 - 14.13 0.024
TGFB codon 10 TT recipient genotype 0.72 0.07 0.007 - 0.61 0.017
TGFB codon 10 TT donor genotype 2.71 7.21 1.01 - 51.29 0.049
IFNG UTR5644 TT recipient genotype 1.16 5.83 1.12 - 30.19 0.036
IFNG UTR5644 TT donor genotype 0.72 0.16 0.04 - 0.68 0.013
Table 3. Multivariate analysis of gene polymorphisms significantly associated 
with CAN
ORadj = adjusted for HLA pairing, MCP1 at position -1025 recipient genotype, MCP-1 at position -1025 donor 
genotype, IL1B SNP at position -511 (T allele) recipient genotype, IL1B SNP at position -511 (C allele) donor 
genotype, IL1R (pstl 1970) recipient genotype, IL1R (pstl 1970) donor genotype, IL1B at position +3962 (C allele) 
recipient genotype and the other genotypes in this table. 
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known variables when looking into multi-factorial 
susceptibility helps highlight hidden differences. Thus, 
our study groups were matched for donor type and 
age, HLA compatibility, presence of hypertension, 
dyslipidemia, number of pre-transplant transfusions, 
CMV positivity, and immunosuppressive regimen. Not 
unexpectedly, however, we were not able to control two 
well-known risk factors, namely the number of acute 
rejection episodes and hyperuricemia (27), which were 
significantly increased in the CAN group.
However, the data we have obtained are generally 
in accordance with the published literature on the 
subject (28-30). 
CONCLUSION
Our results highlight the importance of donor cytokine 
genotyping and show that cytokine polymorphisms 
present in the grafted tissue might, indeed, contribute to 
the development of CAN. The combination of recipient 
and donor genotyping may help choose additional or 
alternative therapeutic approaches for renal transplant 
patients at higher risk, such as the early introduction of 
MMF or other drugs with a potential curbing effect on 
the development of CAN.
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